See more : Most Kwai Chung Limited (1716.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Imugene Limited (IUGNF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imugene Limited, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Castor Maritime Inc. (CTRM) Income Statement Analysis – Financial Results
- Avistar Communications Corporation (AVSR) Income Statement Analysis – Financial Results
- Asia Pacific Wire & Cable Corporation Limited (APWC) Income Statement Analysis – Financial Results
- EVT Limited (EVT.AX) Income Statement Analysis – Financial Results
- RiskOn International, Inc. (ROI) Income Statement Analysis – Financial Results
Imugene Limited (IUGNF)
About Imugene Limited
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 11.78M | 12.97M | 7.23M | 4.13M | 4.13M | 1.84M | 1.16M | 1.56M | 638.68K | 538.31K | 207.22K | 235.91K | 2.23M | 0.00 | 0.00 | 0.00 | 374.56K | 0.00 | 0.00 | 0.00 | 19.00 | 1.29M | 114.24K | 0.00 | 0.00 | 0.00 | 3.86M | 278.00K | 188.00K | 0.00 | 0.00 |
| Cost of Revenue | 5.84M | 2.20M | 2.41M | 1.96M | 82.50K | 63.26K | 2.68K | 1.74K | 1.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 175.00K | 107.20K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -5.84M | 9.57M | 10.56M | 5.27M | 4.05M | 4.06M | 1.84M | 1.16M | 1.56M | 638.68K | 538.31K | 207.22K | 235.91K | 2.23M | 0.00 | 0.00 | 0.00 | 374.56K | 0.00 | 0.00 | 0.00 | 19.00 | 1.12M | 7.04K | 0.00 | 0.00 | 0.00 | 3.86M | 278.00K | 188.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 81.29% | 81.44% | 72.86% | 98.00% | 98.47% | 99.85% | 99.85% | 99.93% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 100.00% | 86.45% | 6.17% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 86.89M | 30.86M | 36.61M | 15.36M | 9.36M | 7.61M | 4.15M | 2.47M | 2.70M | 1.67M | 469.46K | 603.32K | 285.44K | 491.69K | 522.34K | 466.48K | 1.32M | 1.08M | 845.02K | 810.38K | 885.79K | 943.96K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 17.77M | 12.10M | 9.44M | 4.29M | 3.81M | 1.21M | 894.06K | 1.09M | 875.05K | 762.51K | 1.08M | 572.11K | 1.05M | 976.87K | 1.69M | 853.93K | 1.14M | 568.12K | 972.27K | 784.11K | 548.16K | 0.00 | 1.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 506.52K | 334.90K | 154.85K | 282.34K | 426.25K | 0.00 | 318.69K | 479.26K | 340.97K | 42.01K | 51.31K | 0.00 | 0.00 | 0.00 | 197.79K | 38.21K | 0.00 | 0.00 | 247.50K | 249.78K | 0.00 | 0.00 | 562.34K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 48.21M | 18.22M | 12.43M | 9.59M | 4.58M | 4.23M | 1.21M | 894.06K | 1.09M | 875.05K | 804.53K | 1.14M | 572.11K | 1.05M | 976.87K | 1.69M | 853.93K | 1.14M | 568.12K | 1.22M | 1.03M | 548.16K | 0.00 | 1.58M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 11.53M | 12.84M | 7.20M | 4.07M | 4.21M | 1.75M | 1.14M | 1.50M | 679.52K | 883.99K | 156.66K | 114.50K | -171.66K | 312.12K | 3.17M | 340.63K | 372.99K | 169.77K | 254.77K | 43.00K | 509.06K | -466.00K | -1.30M | -4.40M | -4.90M | -4.52M | -3.86M | 593.00K | 747.00K | 766.00K | 262.00K |
| Operating Expenses | 135.09M | 49.09M | 50.67M | 25.67M | 14.88M | 12.39M | 5.78M | 3.69M | 4.27M | 2.88M | 1.34M | 1.74M | 1.40M | 1.89M | 2.12M | 2.76M | 2.56M | 3.04M | 3.15M | 2.51M | 2.44M | 2.43M | 328.00K | 2.58M | -4.40M | -4.90M | -4.52M | 1.39M | 871.00K | 935.00K | 766.00K | 262.00K |
| Cost & Expenses | 140.93M | 51.29M | 50.67M | 25.67M | 14.88M | 12.39M | 5.78M | 3.69M | 4.27M | 2.88M | 1.34M | 1.74M | 1.40M | 1.89M | 2.12M | 2.76M | 2.56M | 3.04M | 3.15M | 2.51M | 2.44M | 2.43M | 503.00K | 2.69M | -4.40M | -4.90M | -4.52M | 1.39M | 871.00K | 935.00K | 766.00K | 262.00K |
| Interest Income | 4.52M | 1.88M | 192.25K | 126.57K | 302.19K | 414.89K | 94.33K | 35.43K | 39.40K | 38.36K | 27.10K | 23.21K | 8.68K | 10.25K | 44.02K | 76.61K | 67.21K | 101.69K | 196.56K | 134.73K | 80.60K | 29.47K | 12.00K | 8.32K | 0.00 | 0.00 | 0.00 | 59.00K | 14.00K | 133.00K | 79.00K | 0.00 |
| Interest Expense | 478.36K | 27.45K | 106.74K | 111.03K | 5.03K | 6.11K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 180.95K | 18.00K | 27.00K | 28.00K | 68.00K | 97.00K | 0.00 | 33.00K | 23.00K |
| Depreciation & Amortization | 5.84M | 2.20M | 2.41M | 1.96M | 82.50K | 63.26K | 2.68K | 1.74K | 1.16K | 2.25M | 676.00 | 676.00 | 172.11K | 343.15K | 343.01K | 343.18K | 343.85K | 345.71K | 346.65K | 347.67K | 348.59K | 132.23K | 328.00K | 439.64K | 0.00 | 0.00 | 0.00 | 572.00K | 581.00K | 491.00K | 328.00K | 163.00K |
| EBITDA | -135.09M | -37.26M | -37.45M | -18.24M | -10.42M | -7.71M | -5.78M | -3.68M | -4.27M | -194.89K | -796.82K | -1.74M | -995.33K | 682.09K | -1.78M | -2.41M | -2.22M | -2.69M | -2.81M | -2.17M | -1.62M | -2.30M | -770.00K | -3.42M | -4.40M | -4.90M | -4.52M | -2.11M | -4.15M | -1.51M | -871.00K | -305.00K |
| EBITDA Ratio | 0.00% | -416.80% | -288.78% | -252.23% | -252.08% | -186.70% | -313.88% | -316.56% | -272.82% | -408.73% | 66.03% | -839.09% | 463.67% | 30.63% | 0.00% | 0.00% | 0.00% | -619.88% | 0.00% | 0.00% | 0.00% | -12,085,773.68% | -59.61% | -2,994.51% | 0.00% | 0.00% | 0.00% | -54.78% | -1,491.73% | -804.79% | 0.00% | 0.00% |
| Operating Income | -140.93M | -51.29M | -37.66M | -18.34M | -10.50M | -7.77M | -5.78M | -3.69M | -4.27M | -2.61M | 355.45K | -1.74M | 921.74K | 338.94K | -2.12M | -2.76M | -2.56M | -2.67M | -3.15M | -2.51M | -1.97M | -2.43M | -1.10M | -3.86M | -4.40M | -4.90M | -4.52M | -2.69M | -4.73M | -2.00M | -1.20M | -468.00K |
| Operating Income Ratio | 0.00% | -435.51% | -290.35% | -253.67% | -254.07% | -188.23% | -314.03% | -316.71% | -272.89% | -408.73% | 66.03% | -839.41% | 390.71% | 15.22% | 0.00% | 0.00% | 0.00% | -712.18% | 0.00% | 0.00% | 0.00% | -12,781,710.53% | -85.00% | -3,379.35% | 0.00% | 0.00% | 0.00% | -69.60% | -1,700.72% | -1,065.96% | 0.00% | 0.00% |
| Total Other Income/Expenses | -13.37M | 1.60M | -165.91K | -20.76K | 237.35K | 486.39K | 3.50K | 14.28K | -26.10K | -194.89K | -1.32M | -27.35K | -1.97M | -159.40K | 358.00K | 3.01M | 410.55K | 106.26K | 712.98K | 396.03K | -819.82K | 384.41K | -1.57M | -180.95K | -18.41K | -27.00K | -28.00K | -6.04M | -3.65M | -766.00K | 295.00K | 140.00K |
| Income Before Tax | -154.30M | -49.66M | -37.87M | -18.46M | -10.51M | -7.78M | -3.93M | -2.51M | -2.73M | -2.44M | -2.12M | -1.56M | -3.13M | 179.54K | -1.77M | 252.50K | -2.15M | -2.56M | -2.44M | -2.12M | -2.79M | -2.04M | -782.00K | -4.04M | -4.42M | -4.93M | -4.55M | -2.18M | -4.24M | -1.51M | -904.00K | -328.00K |
| Income Before Tax Ratio | 0.00% | -421.62% | -291.98% | -255.21% | -254.19% | -188.39% | -213.69% | -215.33% | -174.56% | -382.16% | -393.07% | -752.61% | -1,328.22% | 8.06% | 0.00% | 0.00% | 0.00% | -683.81% | 0.00% | 0.00% | 0.00% | -10,758,515.79% | -60.54% | -3,537.75% | 0.00% | 0.00% | 0.00% | -56.54% | -1,526.62% | -804.79% | 0.00% | 0.00% |
| Income Tax Expense | -4.62M | -11.74M | 12.94M | 7.31M | 4.08M | 4.21M | -97.01K | -37.17K | -39.40K | -2.01M | 1.66M | -23.21K | 2.08M | -236.00K | -230.00K | -397.79K | -238.74K | -257.05K | -252.06K | -2.12M | -2.79M | -2.04M | -782.00K | -4.04M | -4.42M | -4.93M | -4.55M | -2.18M | -4.24M | -1.51M | -904.00K | -328.00K |
| Net Income | -149.68M | -37.91M | -37.87M | -18.46M | -10.51M | -7.78M | -3.93M | -2.51M | -2.73M | -2.44M | -2.12M | -1.56M | -3.13M | 415.54K | -1.54M | 650.29K | -1.91M | -2.30M | -2.19M | -1.79M | -2.12M | 699.06K | -782.00K | -4.04M | -4.42M | -4.93M | -4.55M | -2.18M | -4.24M | -2.14M | -875.00K | 243.00K |
| Net Income Ratio | 0.00% | -321.92% | -291.98% | -255.21% | -254.19% | -188.39% | -213.69% | -215.33% | -174.56% | -382.16% | -393.07% | -752.61% | -1,328.22% | 18.66% | 0.00% | 0.00% | 0.00% | -615.19% | 0.00% | 0.00% | 0.00% | 3,679,200.00% | -60.54% | -3,537.75% | 0.00% | 0.00% | 0.00% | -56.54% | -1,526.62% | -1,135.64% | 0.00% | 0.00% |
| EPS | -0.02 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | -0.01 | 0.00 | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 | -0.04 | -1.60 | -1.84 | -2.27 | -2.35 | -1.37 | -2.92 | -1.53 | -0.83 | 0.34 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | 0.00 | -0.01 | 0.00 | -0.01 | -0.02 | -0.02 | -0.01 | -0.02 | -0.02 | -0.04 | -1.60 | -1.84 | -2.27 | -2.35 | -1.37 | -2.92 | -1.53 | -0.83 | 0.34 |
| Weighted Avg Shares Out | 7.09B | 6.28B | 5.64B | 4.66B | 4.07B | 3.58B | 2.64B | 2.09B | 1.33B | 1.19B | 695.41M | 327.84M | 144.93M | 144.93M | 144.93M | 144.93M | 137.66M | 132.17M | 132.17M | 121.58M | 109.03M | 71.24M | 21.14M | 2.52M | 2.40M | 2.17M | 1.94M | 1.59M | 1.45M | 1.40M | 1.05M | 292.05K |
| Weighted Avg Shares Out (Dil) | 7.09B | 6.28B | 5.64B | 4.66B | 4.07B | 3.58B | 2.64B | 2.09B | 1.33B | 1.19B | 695.41M | 327.84M | 144.93M | 144.93M | 144.93M | 164.04M | 137.66M | 132.17M | 132.17M | 121.58M | 109.03M | 71.24M | 21.14M | 2.52M | 2.40M | 2.17M | 1.94M | 1.59M | 1.45M | 1.40M | 1.05M | 292.05K |
Imugene secures clinical trial supply agreement with Merck KGaA and Pfizer for HER-Vaxx gastric cancer trial
Imugene Limited (ASX:IMU, OTC:IUGNF) has advanced another treatment in its development pipeline through a clinical trial supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc (NYSE:PFE) to evaluate the safety and efficacy of Imugene's HER-Vaxx, in combination with avelumab, in patients with HER-2...
Imugene attracts Buy rating and upgraded price target of A$0.62 from ROTH Capital Partners
Imugene Limited (ASX:IMU, OTC:IUGNF), a clinical-stage immuno-oncology company developing a range of novel immunotherapies, has received a Buy rating from Roth Capital Partners as well as an updated share price target of A$0.62, up from A$0.43. The research report and...
Imugene and Eureka Therapeutics collaborate to accelerate advancement of oncolytic virus and T-cell therapy in solid tumours
Imugene Ltd and Eureka Therapeutics, Inc have entered into a strategic collaboration to evaluate Imugene's CD19 oncolytic virus onCARlytics technology in combination with Eureka's anti-CD19 ARTEMIS® T-cell therapy for the treatment of solid tumours. The collaboration has the potential to address...
Imugene and City of Hope® dose first patient in Phase I clinical trial
Imugene Limited collaborator City of Hope® has dosed its first patient in its Phase I clinical trial of oncolytic virotherapy candidate, CHECKvacc. Along with City of Hope, a world-renowned independent cancer research and treatment centre, IMU is investigating the safety...
Imugene granted HER-Vaxx immunotherapy patent in Japan
Imugene Limited, a clinical-stage immuno-oncology company, has received a notice of grant from the Japanese Patent Office for patent application number 2018-505505 which protects its HER-Vaxx immunotherapy applied in the treatment of HER2 positive gastric cancer. The patent titled 'A Vaccine Composition and...
Imugene upgraded to Buy and target price boosted to 52 cents by Bell Porter on back of capital raise and new HER vaxx trials
Imugene Limited (ASX:IMU, OTC:IUGNF) has received another boost with news that broker Bell Porter has upgraded the company's shares to a Buy (Speculative) from a Hold and more than doubling its target price from A$0.25 to A$0.52. This comes on the...
Imugene reveals encouraging HER-Vaxx gastric cancer data, plans three new trials
Imugene Limited, a clinical-stage immune-oncology company, has revealed secondary efficacy endpoint progression-free survival (PFS) data for its HER-Vaxx immunotherapy in HER-2 positive gastric cancer. The Phase 2 HER-Vaxx clinical trial is designed to evaluate the efficacy, safety and immune response...
Imugene welcomes phase-1 trial dosing schedule for third monotherapy cohort of immunotherapy PD1-Vaxx
Imugene Limited has welcomed the dosing schedule for the third monotherapy cohort of its phase-1 trial of the immunotherapy PD1-Vaxx on three patients. Barring any unforeseen clinical observations, the optimal biological dose of 100µg is expected to be ratified at...
Imugene concludes A$95 million raise with heavily oversubscribed share purchase plan
Imugene Limited has raised A$5 million in a heavily oversubscribed share purchase plan (SPP), capping off a A$95 million capital raise to fund its clinical pipeline into 2025. The clinical-stage immune-oncology company will now issue 16.7 million new ordinary shares...
Imugene details the fine print on Celularity partnership
Imugene Limited has provided additional information on a recent partnership with NASDAQ-listed biotech Celurlarity Inc. The clinical-stage immune-oncology company told the local share market it had partnered with Celurlarity to develop an immunotherapy for solid tumours on Thursday, August 5.
Source: https://incomestatements.info
Category: Stock Reports